SciSparc: NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndrome

TEL AVIV, Israel, July 15, 2026 - SciSparc Ltd. revealed that its branch NeuroThera Labs Inc. has started its Phase IIb clinical trial site at Hannover Medical School in Hanover, Germany for SCI-110, a cannabinoid-based treatment for Tourette Syndrome in adults. NeuroThera Labs, a clinical-stage pharmaceutical company under SciSparc, is dedicated to developing innovative therapies for central nervous system conditions. The commencement of the trial marks a significant advancement in the research for treating TS, and signifies a crucial step towards potentially offering relief to those affected by the disorder.